Bayer shares jump 191% since April, analysts set modest price targets

Bayer AG’s shares have risen roughly 191 % from a low in early April 2025 to early 2026, breaking past key resistance levels and entering an overbought zone on the weekly chart. Technical indicators show a bullish RSI crossover at 76 points and a MACD crossover, though a bearish divergence urges caution. Resistance is seen around €56.5‑€58.5, with a longer‑term target band between €51.7 and €114.5 based on Fibonacci retracements.

In June 2026, eleven analysts evaluated the stock. Eight issued a buy rating and three a hold. The consensus target price is €49.23, while the current XETRA price sits at €48.41. Ratings from banks such as DZ Bank, UBS, Barclays, Jefferies, Goldman Sachs and JPMorgan range from €40 to €55, reflecting divergent views on near‑term upside.

Both pieces highlight the dramatic rally, the mixed technical signals, and the range of analyst expectations as investors weigh the sustainability of the price surge.